A Randomized Controlled Clinical Trial on Injective Azithromycin Versus Erythromycin in the Treatment of Respiratory Tract Bacterial Infections.

Hui Wang

2002-01-01

Abstract:OBJECTIVE: To evaluate the clinical efficacy and safety and adverse drug reaction of injective azithromycin in the treatment of respiratory bacteria infection. METHODS: A randomized controlled open clinical trial was carried out. Erythromycin as a controlled drug was 500~750 mg every 12 hours by intravenous infusion. The course of treatment was 7~l4days.Azithromycin as a trial drug was 250mg every 12 hours on the first day; then every 24 hours by intravenous infusion. The course of treatment was 3~5days in the upper respiratory infection and the lower respiratory infection was 5~7days. RESULTS: In the randomized controlled study, 63patients were enrolled in azithromycin group, 61 patients were assessable for safety and 60 patients were assessable for efficacy. While 69 patients were enrolled in erythromycin group, 62 patients were assessed safety and 60 patients assessed efficacy. The clinical effective rate was 95.0%; the bacterial efficacy rate and the bacterial clearance rate were 94.8% respectively. While those of erythromycin group were 80.0%,77.4% and 84.9% respectively. There was not marked difference between the two groups in statistics. Moreover, the dosage and course of drug were marked difference between the two groups. The incidence of adverse reaction was 9.8%and 25.8% respectively. CONCLUSION: Injective azithromycin of new macrolides type is a kind of effective and safe anti-bacterial drug. This is low dose, shorter course, and more little drug adverse reaction.